SAB Biotherapeutics, Inc. (SABS): Total Assets
$172.81M
As of 2025-12-31
$238.21M
As of 2026-06-30
+50.3%
3-year compound annual growth
+25.0%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $172.81M | +291.0% | 2026-03-09, Balance as of period end |
| 2024-12-31 | $44.20M | -47.3% | 2026-03-09, Balance as of period end |
| 2023-12-31 | $83.94M | +64.9% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $50.90M | n/a | 2024-03-29, Balance as of period end |
| 2022-06-30 | $59.41M | n/a | 2023-04-14, Balance as of period end |
| 2022-03-31 | $68.49M | n/a | 2023-04-14, Balance as of period end |
| 2021-12-31 | $81.14M | +43.5% | 2023-04-28, Balance as of period end |
| 2020-12-31 | $56.54M | n/a | 2023-04-28, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | 2025-12-31 | $172.81M | +291.0% |
| Sutro Biopharma, Inc. (STRO) | 2025-12-31 | $173.83M | -55.1% |
| Caribou Biosciences, Inc. (CRBU) | 2025-12-31 | $175.37M | -44.0% |
| Aura Biosciences, Inc. (AURA) | 2025-12-31 | $169.43M | -7.2% |
| Cabaletta Bio, Inc. (CABA) | 2025-12-31 | $165.08M | -10.8% |
| Inhibikase Therapeutics, Inc. (IKT) | 2025-12-31 | $181.20M | +83.8% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $186.08M | +11.8% |
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | $186.53M | -45.4% |
| Compugen Ltd (CGEN) | 2025-12-31 | $156.57M | +36.2% |
Compare SABS, STRO, CRBU, AURA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗